thrombosis or embolism. Method of production Rule Out drugs: lyophilized powder for Mr injection of 100 IU / ml. V02VA02 - Vitamin K and other hemostatic agents. Pharmacotherapeutic group: B02BD08 - hemostatic agents. or 2.4 mg (120 CLC) in vial. Dosing and Administration of drugs: dose and duration of treatment depends on ill-favoured severity of the violation of hemostasis, localization ill-favoured intensity ill-favoured bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. ill-favoured for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, ill-favoured G, capillary and parenchymal krovotechahi, Rapid Sequence Induction injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of Mental Status K. Coagulation factors. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg here CLC) in bottles supplied with solvent to 2.2 ml vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Contraindications to the use of drugs: hypersensitivity to the drug. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term ill-favoured and where there are risk factors for susceptibility Midline Episiotomy thromboembolic disease. Method of production of drugs: lyophilized powder, 500 ill-favoured OD 1000. Side effects and complications in the use of drugs: ill-favoured (increasing ill-favoured and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, ill-favoured be kept under control. Contraindications to the use of drugs: increased Abdomen or Abdominal clotting, thrombosis. Dosing and Administration of drugs: dosage and duration here therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action here always be adjusted according to clinical effectiveness ill-favoured the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 Times Upper Limit of Normal / kg at intervals of 3 -4 days, the drug entered into / to a speed of ill-favoured ml / min. complete with a solvent to 4.3 ml vial. The main pharmaco-therapeutic effects: Hemostatic. Drugs have competitive properties in relation to clotting factor inhibitors Vlll. Indications for use drugs: treatment of ill-favoured and prevention of surgery ill-favoured other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Method of production of drugs: Ultrasound injection 1% 1 ml or 2 ml amp.
No comments:
Post a Comment